Provectus Biopharmaceuticals Geçmiş Kazanç Performansı
Geçmiş kriter kontrolleri 0/6
Provectus Biopharmaceuticals has been growing earnings at an average annual rate of 21.2%, while the Pharmaceuticals industry saw earnings declining at 0.2% annually. Revenues have been growing at an average rate of 61.9% per year.
Anahtar bilgiler
21.2%
Kazanç büyüme oranı
23.2%
EPS büyüme oranı
| Pharmaceuticals Sektör Büyümesi | 6.0% |
| Gelir büyüme oranı | 61.9% |
| Özkaynak getirisi | n/a |
| Net Marj | -408.0% |
| Sonraki Kazanç Güncellemesi | 14 Nov 2024 |
Yakın geçmiş performans güncellemeleri
Güncelleme yok
Recent updates
Gelir ve Gider Dağılımı
Provectus Biopharmaceuticals nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi
| Tarih | Gelir | Kazançlar | G+A Giderleri | Ar-Ge Giderleri |
|---|---|---|---|---|
| 30 Jun 24 | 1 | -3 | 1 | 0 |
| 31 Mar 24 | 1 | -3 | 1 | 0 |
| 31 Dec 23 | 1 | -3 | 1 | 0 |
| 30 Sep 23 | 1 | -3 | 1 | 0 |
| 30 Jun 23 | 1 | -3 | 1 | 0 |
| 31 Mar 23 | 1 | -3 | 2 | 0 |
| 31 Dec 22 | 1 | -4 | 2 | 0 |
| 30 Sep 22 | 1 | -4 | 2 | 0 |
| 30 Jun 22 | 1 | -4 | 2 | 0 |
| 31 Mar 22 | 0 | -5 | 2 | 0 |
| 31 Dec 21 | 0 | -6 | 2 | 0 |
| 30 Sep 21 | 0 | -6 | 2 | 1 |
| 30 Jun 21 | 0 | -6 | 2 | 1 |
| 31 Mar 21 | 0 | -7 | 2 | 2 |
| 31 Dec 20 | 0 | -7 | 2 | 3 |
| 30 Sep 20 | 0 | -7 | 2 | 3 |
| 30 Jun 20 | 0 | -7 | 2 | 3 |
| 31 Mar 20 | 0 | -7 | 2 | 4 |
| 31 Dec 19 | 0 | -7 | 2 | 4 |
| 30 Sep 19 | 0 | -8 | 3 | 4 |
| 30 Jun 19 | 0 | -7 | 3 | 4 |
| 31 Mar 19 | 0 | -7 | 3 | 4 |
| 31 Dec 18 | 0 | -8 | 3 | 5 |
| 30 Sep 18 | 0 | -9 | 4 | 5 |
| 30 Jun 18 | 0 | -10 | 3 | 7 |
| 31 Mar 18 | 0 | -12 | 3 | 8 |
| 31 Dec 17 | 0 | -14 | 5 | 8 |
| 30 Sep 17 | 0 | -17 | 8 | 8 |
| 30 Jun 17 | 0 | -23 | 11 | 8 |
| 31 Mar 17 | 0 | -25 | 13 | 8 |
| 31 Dec 16 | 0 | -29 | 16 | 8 |
| 30 Sep 16 | 0 | -32 | 16 | 11 |
| 30 Jun 16 | 0 | -29 | 16 | 11 |
| 31 Mar 16 | 0 | -28 | 15 | 11 |
| 31 Dec 15 | 0 | -25 | 11 | 11 |
| 30 Sep 15 | 0 | -14 | 10 | 9 |
| 30 Jun 15 | 0 | -12 | 10 | 8 |
| 31 Mar 15 | 0 | -8 | 10 | 6 |
| 31 Dec 14 | 0 | -10 | 11 | 6 |
| 30 Sep 14 | 0 | -28 | 10 | 4 |
| 30 Jun 14 | 0 | -28 | 10 | 4 |
| 31 Mar 14 | 0 | -30 | 10 | 4 |
Kaliteli Kazançlar: PVCT is currently unprofitable.
Büyüyen Kar Marjı: PVCT is currently unprofitable.
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: PVCT is unprofitable, but has reduced losses over the past 5 years at a rate of 21.2% per year.
Büyüme Hızlandırma: Unable to compare PVCT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Kazançlar vs. Sektör: PVCT is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (12.4%).
Özkaynak Getirisi
Yüksek ROE: PVCT's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.